Please Wait...

sgp 130 // Soluble Glycoprotein 130

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Glycoprotein 130 (gp130) is a transmembrane protein which forms a hexamer with two molecules of Interleukin 6 (IL-6) and two molecules of the interleukin 6 receptor (IL-6R). gp130 is also called IL6ST, IL6-β or CD130 and can be detected in serum in a soluble form. The presence of two different soluble gp130 in human serum (90 and 110kDa), might be the result of proteolytic cleavage and/or alternative splicing of the transmembrane protein (Narazaki et al., 1993). In opposition to IL-6R, gp130 expression is not limited to IL-6 responsive cells (Hibi et al., 1990).

gp130 binds different cytokines (IL-6, IL-11, IL-27, CNTF, CLC, CT-1, LIF, OSM) through association with different receptors subunits (Jones et al., 2011). This association between gp130 and receptor subunits is necessary for the signal transduction. On the contrary, when soluble gp130 bind to IL-6, it inhibits the trans activation of the JAK/STAT3 pathway (Calabrese and Rose-John, 2014; Garbers et al., 2015).

 

sgp130 assay is a solid phase enzyme linked immunoassay which has been validated in the laboratory for measurement in human serum.

 

 

Calabrese, L.H., and Rose-John, S. (2014). IL-6 biology: implications for clinical targeting in rheumatic disease. Nat. Rev. Rheumatol. 10, 720–727.

Garbers, C., Aparicio-Siegmund, S., and Rose-John, S. (2015). The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. Curr. Opin. Immunol. 34, 75–82.

Hibi, M., Murakami, M., Saito, M., Hirano, T., Taga, T., and Kishimoto, T. (1990). Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63, 1149–1157.

Jones, S.A., Scheller, J., and Rose-John, S. (2011). Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Invest. 121, 3375–3383.

Narazaki, M., Yasukawa, K., Saito, T., Ohsugi, Y., Fukui, H., Koishihara, Y., Yancopoulos, G.D., Taga, T., and Kishimoto, T. (1993). Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 82, 1120–1126.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Still time to catch up on summer reading on recent developments in #Alzheimer's Disease Fluid Biomarkers here int t… https://t.co/kyQmz7FxlN
bioclinica (Yesterday)
Our clients have substantial success w #eSource, some spanning well over a decade. Still other organizations remain… https://t.co/UwVs6ajPp4
bioclinica (2 days ago)
Our clients have substantial success w #eSource, some spanning well over a decade. Still some in the industry remai… https://t.co/ASuUvN6xb9
bioclinica (4 days ago)
RT @RfwrightLSL: When Do You Think #BYOD (Bring Your Own Device) Will Become Widely Used To Capture PRO Data In #Clinical #Research? https:…
bioclinica (1 week ago)
ICYMI: Our V.P./Head of Neuroscience & Cardiovascular Svcs., Dr. Joyce Suhy, talks about challenges in determining… https://t.co/Lns6B3VPPN
bioclinica (1 week ago)
RT @FCR_News_Today: FDA Issues New Guides on Use of Electronic Health Information in #ClinicalTrials. #ClinicalResearch https://t.co/j8LHV2…
bioclinica (2 weeks ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen